The main pharmaceutical applications concern: pathological conditions of central and peripheral nervous system, with special interest on the endocannabinoid system (cannabinoid receptor ligands and FAAH and/or MGL activity modulators) and serotoninergic field (5-HT3 receptor ligands), and viral infections, with special attention to HIV-1 activity inhibitors (integrase and/or NNRT inhibitors). Recently, given the close interaction between the endocannabinoi and endovannilloid systems, a study was undertaken in order to identify new potent ligands of TRPV1 receptors.
Researchers involved
Collaborations:
- Vincenzo Di Marzo, Alessia Ligresti (Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Pozzuoli, Napoli)
- Roger Guy Pertwee, Maria Grazia Cascio, Pietro Marini (Institute of Medical Sciences, University of Aberdeen, Scotland U.K.)
- Francesca Aiello (Dipartimento di Farmacia e Scienze della Salute e della Nutrizione, Università della Calabria, Arcavacata di Rende, Cosenza)
- Stefano Alcaro, Anna Artese (Dipartimento Scienze della Salute, Università degli Studi “Magna Grecia”, Catanzaro)
- Giuseppe Valacchi (Dipartimento di Scienze della Vita e Biotecnologie, Università di Ferrara)